Abstract

Here, we develop a simple molecular test for SARS-CoV-2 in saliva based on reverse transcription loop-mediated isothermal amplification (RT-LAMP). The test has two steps: 1) heat saliva with a stabilization solution, and 2) detect virus by incubating with a primer/enzyme mix. After incubation, saliva samples containing the SARS-CoV-2 genome turn bright yellow. Because this test is pH dependent, it can react falsely to some naturally acidic saliva samples. We report unique saliva stabilization protocols that rendered 295 healthy saliva samples compatible with the test, producing zero false positives. We also evaluated the test on 278 saliva samples from individuals who were infected with SARS-CoV-2 but had no symptoms at the time of saliva collection, and from 54 matched pairs of saliva and anterior nasal samples from infected individuals. The Saliva TwoStep test described herein identified infections with 94% sensitivity and >99% specificity in individuals with sub-clinical (asymptomatic or pre-symptomatic) infections.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Qing Yang

    Department of Molecular Cellular and Developmental Biology, University of Colorado Boulder, Boulder, United States
    Competing interests
    Qing Yang, Some of the authors of this study (NRM, QY, CLP, SLS) are founders of Darwin Biosciences, who licenses the Saliva TwoStep assay described herein..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9053-3158
  2. Nicholas R Meyerson

    Molecular, Cellular, and Developmental Biology, University of Colorado Boulder, Boulder, United States
    Competing interests
    Nicholas R Meyerson, Some of the authors of this study (NRM, QY, CLP, SLS) are founders of Darwin Biosciences, who licenses the Saliva TwoStep assay described herein..
  3. Stephen K Clark

    BioFrontiers Institute, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
  4. Camille L Paige

    BioFrontiers Institute, University of Colorado Boulder, Boulder, United States
    Competing interests
    Camille L Paige, Some of the authors of this study (NRM, QY, CLP, SLS) are founders of Darwin Biosciences, who licenses the Saliva TwoStep assay described herein..
  5. Will T Fattor

    BioFrontiers Institute, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
  6. Alison R Gilchrist

    Department of Molecular Cellular and Developmental Biology, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
  7. Arturo Barbachano-Guerrero

    BioFrontiers Institute, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
  8. Benjamin G Healy

    Department of Mechanical Engineering, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
  9. Emma R Worden-Sapper

    Department of Molecular Cellular and Developmental Biology, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
  10. Sharon S Wu

    BioFrontiers Institute, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
  11. Denise Muhlrad

    Department of Chemistry and Biochemistry, Howard Hughes Medical Institute, University of Colorado, Boulder, United States
    Competing interests
    No competing interests declared.
  12. Carolyn J Decker

    Chemistry and Biochemistry, Howard Hughes Medical Institute, University of Colorado, Boulder, United States
    Competing interests
    No competing interests declared.
  13. Tassa K Saldi

    Integrated Physiology and Molecular, Cellular and Developmental Biology, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
  14. Erika Lasda

    BioFrontiers Institute, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
  15. Patrick Gonzales

    Integrative Physiology, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
  16. Morgan R Fink

    BioFrontiers Institute, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0567-3234
  17. Kimngan L Tat

    BioFrontiers Institute, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
  18. Cole R Hager

    BioFrontiers Institute, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
  19. Jack C Davis

    BioFrontiers Institute, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
  20. Christopher D Ozeroff

    BioFrontiers Institute, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
  21. Gloria R Brisson

    Wardenburg Health Center, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
  22. Matthew B McQueen

    Integrated Physiology, University of Colorado, Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
  23. Leslie A Leinwand

    BioFrontiers Institute, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1470-4810
  24. Roy Parker

    Department of Chemistry and Biochemistry, Howard Hughes Medical Institute, University of Colorado, Boulder, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8412-4152
  25. Sara L Sawyer

    Department of Molecular Cellular and Developmental Biology, University of Colorado Boulder, Boulder, United States
    For correspondence
    ssawyer@colorado.edu
    Competing interests
    Sara L Sawyer, Some of the authors of this study (NRM, QY, CLP, SLS) are founders of Darwin Biosciences, who licenses the Saliva TwoStep assay described herein.Senior editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6965-1085

Funding

Burroughs Wellcome Fund (PDEP)

  • Nicholas R Meyerson

Burroughs Wellcome Fund (PATH)

  • Sara L Sawyer

National Institutes of Health (DP1-DA-046108)

  • Sara L Sawyer

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: This study was approved by the University of Colorado Boulder Institutional Review Board. Saliva samples for assay development were collected under protocol 20-0068. Adult participants were consented verbally and donated up to 2mL of whole saliva for use as a reagent in optimization and limit of detection experiments. Data on human subjects is aggregated from University of Colorado Boulder operational COVID-19 surveillance testing activities. For this reason, the research herein did not fall under IRB purview.

Copyright

© 2021, Yang et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,000
    views
  • 382
    downloads
  • 35
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Qing Yang
  2. Nicholas R Meyerson
  3. Stephen K Clark
  4. Camille L Paige
  5. Will T Fattor
  6. Alison R Gilchrist
  7. Arturo Barbachano-Guerrero
  8. Benjamin G Healy
  9. Emma R Worden-Sapper
  10. Sharon S Wu
  11. Denise Muhlrad
  12. Carolyn J Decker
  13. Tassa K Saldi
  14. Erika Lasda
  15. Patrick Gonzales
  16. Morgan R Fink
  17. Kimngan L Tat
  18. Cole R Hager
  19. Jack C Davis
  20. Christopher D Ozeroff
  21. Gloria R Brisson
  22. Matthew B McQueen
  23. Leslie A Leinwand
  24. Roy Parker
  25. Sara L Sawyer
(2021)
Saliva TwoStep for rapid detection of asymptomatic SARS-CoV-2 carriers
eLife 10:e65113.
https://doi.org/10.7554/eLife.65113

Share this article

https://doi.org/10.7554/eLife.65113

Further reading

    1. Medicine
    2. Microbiology and Infectious Disease
    3. Epidemiology and Global Health
    4. Immunology and Inflammation
    Edited by Jos WM van der Meer et al.
    Collection

    eLife has published articles on a wide range of infectious diseases, including COVID-19, influenza, tuberculosis, HIV/AIDS, malaria and typhoid fever.

    1. Genetics and Genomics
    2. Microbiology and Infectious Disease
    Dániel Molnár, Éva Viola Surányi ... Judit Toth
    Research Article

    The sustained success of Mycobacterium tuberculosis as a pathogen arises from its ability to persist within macrophages for extended periods and its limited responsiveness to antibiotics. Furthermore, the high incidence of resistance to the few available antituberculosis drugs is a significant concern, especially since the driving forces of the emergence of drug resistance are not clear. Drug-resistant strains of Mycobacterium tuberculosis can emerge through de novo mutations, however, mycobacterial mutation rates are low. To unravel the effects of antibiotic pressure on genome stability, we determined the genetic variability, phenotypic tolerance, DNA repair system activation, and dNTP pool upon treatment with current antibiotics using Mycobacterium smegmatis. Whole-genome sequencing revealed no significant increase in mutation rates after prolonged exposure to first-line antibiotics. However, the phenotypic fluctuation assay indicated rapid adaptation to antibiotics mediated by non-genetic factors. The upregulation of DNA repair genes, measured using qPCR, suggests that genomic integrity may be maintained through the activation of specific DNA repair pathways. Our results, indicating that antibiotic exposure does not result in de novo adaptive mutagenesis under laboratory conditions, do not lend support to the model suggesting antibiotic resistance development through drug pressure-induced microevolution.